Ranxiao Zhuang

Dr. Ranxiao Zhuang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
YCYu Cao
Yu Cao
YLYang Lu
Yang Lu
HZHuajian Zhu
Huajian Zhu
JZJiankang Zhang
Jiankang Zhang
JSJiaan Shao
Jiaan Shao

1 March 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XLXing Liu
Xing Liu
YSYidan Shao
Yidan Shao
YLYunjiang Li
Yunjiang Li
ZCZuhua Chen
Zuhua Chen
TSTingting Shi
Tingting Shi
XPXuwang Pan
Xuwang Pan
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world, mainly because of its powerful pro-connective tissue proliferation matrix and immunosuppressive tumor microenvironment (TME), which promote tumor progression and metastasis. In addition, the extracellular matrix leads to vascular collapse, increased interstitial fluid pressure, and obstruction of lymphatic return, thereby hindering effective drug delivery, deep penetration, and immune cell infiltration. Therefore, reshaping the TME to enhance tumor perfusion, increase deep drug penetration, and reverse immune suppression has become a key therapeutic strategy. Traditional therapies for PDAC, including surgery, radiation, and chemotherapy, face significant limitations. Surgery is challenging due to tumor location and growth, while chemotherapy and radiation are hindered by the dense extracellular matrix and immunosuppressive TME. In recent years, the advancement of nanotechnology has provided new opportunities to improve drug efficacy. Nanoscale drug delivery systems (NDDSs) provide several advantages, including improved drug stability in vivo, enhanced tumor penetration, and reduced systemic toxicity. However, the clinical translation of nanotechnology in PDAC therapy faces several challenges. These include the need for precise targeting and control over drug release, potential immune responses to the nanocarriers, and the scalability and cost-effectiveness of production. This article provides an overview of the latest nanobased methods for achieving better therapeutic outcomes and overcoming drug resistance. We pay special attention to TME-targeted therapy in the context of PDAC, discuss the advantages and limitations of current strategies, and emphasize promising new developments. By emphasizing the enormous potential of NDDSs in improving the treatment outcomes of patients with PDAC, while critically discussing the limitations of traditional therapies and the challenges faced by nanotechnology in achieving clinical breakthroughs, our review paves the way for future research in this rapidly developing field.

27 January 2020 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
CZChong Zhang
Chong Zhang
HZHuajian Zhu
Huajian Zhu
JSJiaan Shao
Jiaan Shao
RHRuoyu He
Ruoyu He
JXJianjun Xi
Jianjun Xi
JZJiankang Zhang
Jiankang Zhang

11 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTingting Shi
Tingting Shi
XYXingxin Yang
Xingxin Yang
HZHongping Zhou
Hongping Zhou
JXJianjun Xi
Jianjun Xi
JSJingjing Sun
Jingjing Sun
RZRanxiao Zhuang
Ranxiao Zhuang
Non-alcoholic fatty liver disease (NAFLD) is becoming one of the world's most common chronic liver diseases in childhood, yet no therapy is available that has been approved by the food and drug administration (FDA). Previous studies have reported that telomere and telomerase are involved the development and progression of NAFLD. This study was designed to investigate the potential beneficial effects of activated carbon N-acetylcysteine (ACNAC) microcapsules on the development of NAFLD in young rats as well as the underlying mechanism(s) involved. Three-week old male Sprague Dawley rats were given high-fat diet (HFD) with/without ACNAC treatment for 7 consecutive weeks. Liver pathologies were determined by hematoxylin and eosin (H&E) and Oil Red O staining, as well as by changes in biochemical parameters of plasma alanine transaminase (ALT) and aspartate transaminase (AST) levels, respectively. Glucose homeostasis was evaluated by the glucose tolerance test and the liver telomere length and activity were measured by real time PCR and telomeric repeat amplification protocol (TRAP). Western blot analysis was performed to determine the expression level of Bcl-2, Bax and Caspase-3. Our results demonstrated that ACNAC supplementation improved liver pathologies of rats that received long-term HFD feeding. ACNAC supplementation prevented HFD-induced telomere shortening and improved telomerase activity. Moreover, in comparison to HFD-fed rats, ACNAC supplementation markedly increased the expression of Bcl-2, but significantly decreased the expression of Bax and Caspase-3 in juvenile rats. Together, these results indicate that ACNAC may be a promising choice for preventing and treating NAFLD among children.

1 December 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JZJiankang Zhang
Jiankang Zhang
LGLixin Gao
Lixin Gao
JXJianjun Xi
Jianjun Xi
LSLi Sheng
Li Sheng
YZYanmei Zhao
Yanmei Zhao
JLJia Li
Jia Li

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
TSTingting Shi
Tingting Shi
LYLiping Yu
Liping Yu
RZRanxiao Zhuang
Ranxiao Zhuang
JXJianjun Xi
Jianjun Xi
RHRuoyu He
Ruoyu He
XYXingxin Yang
Xingxin Yang
Metabolic associated fatty liver disease (MAFLD) is a multifactorial systemic disorder that occurs in the absence of excessive alcohol consumption. The disease is characterized by fatty degeneration and fat accumulation in liver parenchymal cells, the incidence of which is increasing annually, particularly in younger adults. MAFLD is caused by genetic and metabolism related disorders, of which mitochondrial dysfunction is the major contributor. Natural products can relieve MAFLD through restoring mitochondrial function. In this article, we describe the relationship between mitochondria and MAFLD and discuss the beneficial effects of natural products as a future anti‐MAFLD strategy. Significance Statement. We herein propose that the development of mitochondrial regulators/nutrients from natural products can remedy mitochondrial dysfunction which represents an attractive strategy for the treatment of MAFLD. Furthermore, the mitochondrial regulation of natural products can provide new insight into the underlying mechanisms of action of natural products used for future MAFLD therapeutics.